The review will deal with drugs in phase III testing for HIV treatment including two new integrase inhibitors: dolutegravir (DTG), elvitegravir (ELV) and the non-catalytic site integrase inhibitor (BI224436). New drug reviews will also include recent data for the Zink Finger Nuclease (ZFN) that targets cure based on the experience with “the Berlin patient.” Early results have shown engraftment with suppression of VL during ART interruption. Recent data will also be reviewed on the novel lgG4 humanized monoclonal antibody (Ibalizumab) that binds CD4 cells to block viral entry; this agent is given parenterally every 2–4 weeks and targets patients failing alternative regimens. Other topics will be rilpivirine, novel HIV regimens such as NRTI-sparing regimens and the new data supporting ART to prevent HIV transmission (PrEP and protocol 052).
© 2012 Lippincott Williams & Wilkins, Inc.